Osteogenesis Imperfecta - Pipeline Review, H1 2017

Publisher Name :
Date: 08-Mar-2017
No. of pages: 45
Price : Single User: US $ 2000  US $ 1600 Corporate User: US $ 6000  US $ 4500
Inquire Before Buying
This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteogenesis Imperfecta - Pipeline Review, H1 2017, provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break easily, often from little or no apparent cause. This disease is caused by a defect, or flaw, in the gene that produces type 1 collagen, a protein used to create bone. Symptoms include bone deformities, multiple broken bones, loose joints, weak teeth, heart defects and respiratory problems. Treatment includes bisphosphonates and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteogenesis Imperfecta - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 3 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta (Genetic Disorders).

  • The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Osteogenesis Imperfecta (Genetic Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Osteogenesis Imperfecta (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Osteogenesis Imperfecta - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteogenesis Imperfecta - Overview
Osteogenesis Imperfecta - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Osteogenesis Imperfecta - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteogenesis Imperfecta - Companies Involved in Therapeutics Development
Amgen Inc
Bone Therapeutics SA
Genzyme Corp
Mereo Biopharma Group Plc
Osteogenesis Imperfecta - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPS-804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAL-436/9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Osteogenesis Imperfecta - Product Development Milestones
Featured News & Press Releases
Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme
Jun 30, 2016: Mereo's BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta
Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for osteogenesis imperfecta
Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Osteogenesis Imperfecta, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Osteogenesis Imperfecta - Pipeline by Amgen Inc, H1 2017
Osteogenesis Imperfecta - Pipeline by Bone Therapeutics SA, H1 2017
Osteogenesis Imperfecta - Pipeline by Genzyme Corp, H1 2017
Osteogenesis Imperfecta - Pipeline by Mereo Biopharma Group Plc, H1 2017

List of Figures

Number of Products under Development for Osteogenesis Imperfecta, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 35
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and som......
  • Behcet Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 65
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2017, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, h......
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 64
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2017, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headach......
  • Post Menopausal Osteoporosis - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 73
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2017, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone stru......
  • Pompe Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pompe Disease - Pipeline Review, H1 2017, provides an overview of the Pompe Disease (Metabolic Disorders) pipeline landscape.Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). This enzyme is needed to break down glycogen, a form of sugar stored in muscle cells. When too much glycogen builds up ......
  • Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wri......
  • LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2017
    Published: 12-May-2017        Price: US 1250 Onwards        Pages: 57
    DelveInsight's, "LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. This report provides information on the therapeutic development based on the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists dealing with all the pipeline......
  • Radiation Toxicity - Pipeline Review, H1 2017
    Published: 09-May-2017        Price: US 2000 Onwards        Pages: 202
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal ......
  • Guillain-Barre Syndrome - Pipeline Review, H1 2017
    Published: 09-May-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2017, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrica......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs